Navigation Links
Sabinsa Corporation Validates Safety of Garcinia Cambogia Extract in Light of Hydroxycut Warning
Date:6/9/2009

PISCATAWAY, N.J., June 9 /PRNewswire/ -- Sabinsa Corporation has issued a position paper on the safety of HCA as found in its branded ingredient products, specifically the Citrin(R) range of extracts and GarCitrin(R). This paper, which reviews and analyzes the published safety documentation of Garcinia cambogia extract, its active component hydroxycitric acid and its salts, is available to download from http://www.sabinsa.com and http://www.garcitrin.com.

On May 1, 2009, the FDA issued a warning to consumers, based on adverse event reports, to stop using Hydroxycut products by Iovate Health Sciences Inc., of Oakville, Ontario and distributed by Iovate Health Sciences USA Inc. of Blasdell, NY. Although branded ingredients from Sabinsa Corporation do not occur in Hydroxycut, our scientific integrity dictates that we dispel any reservations on the safety of a healthful, natural, food ingredient, hydroxycitric acid, which forms a part of the active ingredients composition of Hydroxycut.

The active ingredients in an example product in the Hydroxycut line include Garcinia cambogia fruit rind extract (supplying calcium hydroxycitrate and potassium hydroxycitrate); Chromium polynicotinate; Gymnema sylvestre leaf extract; caffeine; Green tea extract (supplying polyphenols, catechins, 15% w/w epigallocatechin gallate (EGCG); White tea extract (supplying polyphenols, catechins, 15% w/w epigallocatechin gallate (EGCG); Oolong tea extract supplying polyphenols, catechins, 15% w/w epigallocatechin gallate (EGCG); Ginger extract (supplying gingerols); Raspberry ketone; and Quercetin dihydrate.

Based on the long history of food use of Garcinia cambogia fruits, the wealth of literature encompassing both preclinical and clinical studies, Sabinsa Corporation's clinical experience with Citrin(R) and 15 years of successful marketing of Citrin(R) extracts, there is no direct epidemiological or clinical evidence linking Garcinia cambogia fruit rind extract with hepatotoxicity. An exhaustive safety review by an independent panel of experts established GRAS-affirmed status for Citrin(R)K, the potassium salt of hydroxycitric acid, in 2007. The safety of G. cambogia extract and its active ingredient (-)-HCA is supported by a variety of animal as well as in vitro experimental studies. Additional evidence from multiple human clinical trials further supports the safety aspects of (-)-HCA. Because of its potential health benefits, there has been considerable effort to elucidate the mechanism of action of (-)-HCA. Relevant biological and toxicological studies on G. cambogia extract and (-)-HCA supporting the safety in use of Citrin(R)K are included in the report.

Sabinsa's mission is to provide alternative and complementary natural products for human nutrition and well-being. Over the past 20 years, Sabinsa has brought to market more than 100 standardized botanical extracts and privately funded several clinical studies in conjunction with prestigious institutions in support of these products. With more than 100 full-time scientists conducting ongoing research in India and the United States, Sabinsa continues to develop and patent phytonutrients for the world market. All products intended for human consumption are certified Kosher, with many certified Halal. For more information, visit http://www.sabinsa.com and http://www.garcitrin.com.

    MEDIA CONTACT:

    Hame Persaud
    hame@sabinsa.com
    T: 732-777-1111

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Sabinsa Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Brooke Franchise Corporation Announces Selected July Results
3. MedThink Communications Retained by NanoBio Corporation
4. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
5. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
6. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
7. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
8. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
9. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
10. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
11. AGA Medical Corporation Receives Approval for the AMPLATZER Muscular Ventricular Septal Defect Occluder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... May 31, 2016 , ... When MetLoop ... knew it was something that contractors should have at their disposal on a ... says Butch, CertainTeed’s Director of Contractor Programs. , As a result, Metloop ...
(Date:5/31/2016)... ... May 31, 2016 , ... The successful implementation of “lean manufacturing” in ... well. However, laboratories have different challenges compared to manufacturing environments. , In order ... lab, METTLER TOLEDO has developed the Lean Lab Checklist . This checklist will ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Spectrum Aquatics has ... new lift has been designed and built with the user in mind. , “Over ... consultants have informed us that an ADA 400 lbs lift is a necessary requirement ...
(Date:5/31/2016)... ... ... a recent interview on The Greenburgh Report radio show hosted by Greenburgh, NY Town ... leading medical insurance advocate Adria Goldman Gross discussed several eye-opening issues that have combined ... the interview with Mr. Feiner that aired on May 7, 2016, Ms. Gross, the ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... on patients with cancer, has added Cancer and Careers to its ... more timely content on continuing successful careers while fighting cancer. , As partners, ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... Kitov Pharmaceuticals ... late-stage drug development, today announced the completion of ... batches required for registration of KIT-302 with the ... Kitov,s announcement in December 2015, that ... primary efficacy endpoint. "We are fortunate ...
(Date:5/26/2016)... India , May 26, 2016 ... drugs market growth is the emergence of new treatments. ... astaxanthin therapies for osteoarthritis treatment. The therapy is expected ... Moreover, Arthritis Research UK is conducting studies to develop ... arcOGEN study, where the genes involved in osteoarthritis are ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
Breaking Medicine Technology: